Vapotherm Inc
NYSE:VAPO
Intrinsic Value
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. [ Read More ]
The intrinsic value of one
VAPO
stock under the Base Case scenario is
18.913
USD.
Compared to the current market price of 1.266 USD,
Vapotherm Inc
is
Undervalued by 93%.
Vapotherm Inc's market capitalization is 7.8m USD.
VAPO stock price is 1.266 USD.
VAPO stock price (1.266 USD) is 93% less than its Intrinsic Value (18.913 USD).
VAPO. Open DCF Valuation
VAPO stock price (1.266 USD) is 93% less than its Relative Value (18.913 USD). Open Relative Valuation
VAPO has downside potential of 21% compared to the average analyst price target.
Open Wall St Estimates
VAPO's Revenue has grown by 3% over the past 12 months.
VAPO's ROIC (Return on Invested Capital) has increased in the last 3 years from -61% to -54%, and is approaching profitability.
VAPO's ROE (Return on Equity) has significantly increased in the last 3 years from -65% to 139%.
VAPO has positive Gross Profit for the last twelve months.
VAPO has negative Operating Income for the last twelve months.
VAPO has negative Net Income for the last twelve months.
VAPO's ROE (Return on Equity) for the past 12 months is very high and is equal to 139%.
VAPO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -54%.
VAPO's Revenue has been falling by 18% per year for the last 3 years.
VAPO's long-term liabilties (133m USD) exceed its long-term assets (78m USD).
VAPO's short-term assets (46m USD) exceed its short-term liabilties (19m USD).
VAPO has negative Free Cash Flow for the last twelve months.
VAPO has positive Net Debt. This means that the company has more debt (107m USD) than cash and short-term investments (10m USD).
VAPO has negative three-year average ROE (Return on Equity): -77%. The company is not efficient at transforming stockholders' equity into net income.
VAPO has negative three-year average ROIC (Return on Invested Capital): -71%. The company is not efficient at using invested capital to generate operating income.
VAPO's D/E (Debt to Equity) is very low and is equal to -1.93.
VAPO's Altman Z-Score is very low and is equal to -10.31.
VAPO doesn't generate enough operating income (-38m USD) to safely cover interest payments on its debt (6m USD).
Fundamental Analysis
Vapotherm Inc
Balance Sheet Decomposition
Vapotherm Inc
| Current Assets | 46.4m |
| Cash & Short-Term Investments | 9.7m |
| Receivables | 10.7m |
| Other Current Assets | 26m |
| Non-Current Assets | 31.2m |
| PP&E | 27.1m |
| Intangibles | 565k |
| Other Non-Current Assets | 3.6m |
| Current Liabilities | 19.1m |
| Accounts Payable | 5.1m |
| Accrued Liabilities | 9.4m |
| Other Current Liabilities | 4.6m |
| Non-Current Liabilities | 113.9m |
| Long-Term Debt | 107.1m |
| Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
Vapotherm Inc
|
Revenue
|
68.7m
USD
|
|
Cost of Revenue
|
-40.3m
USD
|
|
Gross Profit
|
28.3m
USD
|
|
Operating Expenses
|
-66m
USD
|
|
Operating Income
|
-37.7m
USD
|
|
Other Expenses
|
-20.5m
USD
|
|
Net Income
|
-58.2m
USD
|
Free Cash Flow Analysis
Vapotherm Inc
VAPO Profitability Score
Profitability Due Diligence
Vapotherm Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Vapotherm Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
VAPO Solvency Score
Solvency Due Diligence
Vapotherm Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Vapotherm Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VAPO Price Targets Summary
Vapotherm Inc
According to Wall Street analysts, the average 1-year price target for
VAPO
is 1 USD
.
Ownership
VAPO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VAPO Price
Vapotherm Inc
| Average Annual Return | -0.28% |
| Standard Deviation of Annual Returns | 99.43% |
| Max Drawdown | -100% |
| Market Capitalization | 7.8m USD |
| Shares Outstanding | 6 193 850 |
| Percentage of Shares Shorted | 10.2% |
Company Profile
Vapotherm Inc
Country
Industry
Market Cap
Dividend Yield
Description
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
You don't have any saved screeners yet
